Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
chronic lymphocytic leukaemia
melanoma
recurrence
survival
treatment
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
29
01
2022
received:
02
12
2021
accepted:
31
01
2022
pubmed:
15
3
2022
medline:
29
4
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
With new, effective treatments for chronic lymphocytic leukaemia (CLL) the impact of second malignancies is increasingly important. We performed a retrospective case-controlled study examining the effect of CLL and its treatment on melanoma-specific survival and recurrence. A total of 56 patients with melanoma with CLL were matched 1:1 to patients without CLL for age, date of diagnosis, gender and melanoma tumour, node, metastasis (TNM) stage. Multivariate analysis found CLL was associated with significantly worse melanoma-specific mortality (hazard ratio [HR] 2.46, 95% confidence interval [CI] 1.27-4.74, p = 0.007) and recurrence (HR 3.44, 95% CI 1.79-6.63, p < 0.001). Patients with CLL had poor immunotherapy tolerance and prior CLL treatment was not associated with melanoma outcomes.
Identifiants
pubmed: 35286715
doi: 10.1111/bjh.18090
pmc: PMC9314657
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
320-325Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Blood. 2012 Aug 16;120(7):1412-21
pubmed: 22547582
Melanoma Res. 2014 Aug;24(4):401-3
pubmed: 24743053
Leuk Lymphoma. 2018 Mar;59(3):578-582
pubmed: 28771053
Dermatol Surg. 2010 Mar;36(3):368-76
pubmed: 20100262
Blood Cancer J. 2018 Oct 3;8(10):93
pubmed: 30283014
Am J Cancer Res. 2019 Jul 01;9(7):1396-1414
pubmed: 31392077
Leukemia. 2016 Jan;30(1):65-73
pubmed: 26202928
Biometrics. 1978 Dec;34(4):541-54
pubmed: 373811
Curr Med Chem. 2006;13(26):3165-89
pubmed: 17168705
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810369
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
J Clin Oncol. 2015 Oct 1;33(28):3096-104
pubmed: 26240221
Br J Haematol. 2012 Jul;158(2):216-231
pubmed: 22571278
Dermatology. 2013;226(3):274-8
pubmed: 23941917
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
J Clin Oncol. 2020 Feb 20;38(6):567-575
pubmed: 31880964
Lancet. 2018 Apr 14;391(10129):1524-1537
pubmed: 29477250
J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7
pubmed: 1512794
Best Pract Res Clin Haematol. 2010 Mar;23(1):47-59
pubmed: 20620970
Br J Haematol. 2022 May;197(3):320-325
pubmed: 35286715
Br J Dermatol. 2017 Jul;177(1):134-140
pubmed: 28369739
J Immunother. 2021 Jan;44(1):9-15
pubmed: 33290361
N Engl J Med. 2013 Jul 11;369(2):122-33
pubmed: 23724867
Leuk Lymphoma. 2015 Jun;56(6):1643-50
pubmed: 25308294
J Clin Oncol. 2012 Mar 10;30(8):843-9
pubmed: 22331952